ImmuCell Corporation
ICCC
$6.52
$0.345.50%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.30M | 26.49M | 23.84M | 23.22M | 21.28M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.30M | 26.49M | 23.84M | 23.22M | 21.28M |
| Cost of Revenue | 17.90M | 18.15M | 16.94M | 16.65M | 14.89M |
| Gross Profit | 9.41M | 8.35M | 6.89M | 6.58M | 6.39M |
| SG&A Expenses | 5.83M | 5.68M | 5.49M | 5.45M | 5.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.12M | 27.73M | 26.58M | 26.57M | 24.55M |
| Operating Income | 184.50K | -1.23M | -2.74M | -3.35M | -3.27M |
| Income Before Tax | -261.20K | -2.15M | -3.81M | -4.05M | -3.89M |
| Income Tax Expenses | 10.50K | 9.90K | 5.20K | 4.10K | 4.30K |
| Earnings from Continuing Operations | -0.27 | -2.16 | -3.81 | -4.05 | -3.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -271.70K | -2.16M | -3.81M | -4.05M | -3.90M |
| EBIT | 184.50K | -1.23M | -2.74M | -3.35M | -3.27M |
| EBITDA | 2.88M | 1.45M | -49.80K | -633.60K | -537.70K |
| EPS Basic | -0.06 | -0.28 | -0.49 | -0.52 | -0.50 |
| Normalized Basic EPS | -0.04 | -0.15 | -0.26 | -0.31 | -0.30 |
| EPS Diluted | -0.07 | -0.29 | -0.50 | -0.53 | -0.51 |
| Normalized Diluted EPS | -0.04 | -0.15 | -0.26 | -0.31 | -0.30 |
| Average Basic Shares Outstanding | 33.89M | 32.66M | 31.48M | 31.06M | 30.99M |
| Average Diluted Shares Outstanding | 33.89M | 32.66M | 31.48M | 31.06M | 30.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |